deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT05347485

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma

Sponsor: Janssen Scientific Affairs, LLC

Conditions Multiple Myeloma
Interventions Cilta-cel Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Updated 28 times since 2022 Last updated: Apr 24, 2025 Started: May 13, 2022 Primary completion: Nov 30, 2023 Completion: Dec 15, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and is currently completed. Janssen Scientific Affairs, LLC leads this study, which shows 28 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

28 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Apr 2025 — May 2025 [monthly]

    Completed PHASE2

  4. Mar 2025 — Apr 2025 [monthly]

    Completed PHASE2

  5. Feb 2025 — Mar 2025 [monthly]

    Completed PHASE2

▶ Show 23 earlier versions

  1. Jan 2025 — Feb 2025 [monthly]

    Completed PHASE2

  2. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  9. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  11. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  12. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  13. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  14. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  15. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  16. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  17. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  18. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  19. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  20. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  21. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  22. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  23. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Scientific Affairs, LLC
Data source: Janssen Scientific Affairs, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Charlotte, United States , Chicago, United States , Denver, United States , Detroit, United States , Duarte, United States , Hackensack, United States , Houston, United States , Milwaukee, United States and 6 more locations